Loading
This German study assigns additional treatment after surgery according to tumour profiling. Its olaparib arm can accept qualifying tumour-only BRCA alterations.
The registry lists NCT05332561 as recruiting, last updated 2025-03-20. Enrolment is 240 planned participants, an estimate. Interventions: Atezolizumab 1200 mg in 20 ML Injection, Inavolisib, Ipatasertib, Olaparib, Sacituzumab govitecan, Trastuzumab/pertuzumab. Primary measures include Invasive Disease-free Survival (IDFS) as defined by Hudis et al in the entire study population four years after surgery. No results are posted in the registry; this does not exclude separate publications. The current registry lists German sites and no US site. Arm 4 accepts inactivating somatic or germline BRCA1/2, including homozygous deletions, or inactivating germline PALB2, with assignment exclusively determined by the molecular tumour board. Separate arms target separate pathways; the platform is not a combined PARP regimen or proof of adjuvant benefit for somatic-only BRCA.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares PARP, Olaparib, Breast cancer (all types).
Shares PARP, Olaparib, Breast cancer (all types).
Shares PARP, Olaparib, Breast cancer (all types).
Shares PARP, Olaparib, Breast cancer (all types).
Shares PARP, Olaparib, Breast cancer (all types).
Shares PARP, Olaparib, Breast cancer (all types).
Shares Olaparib, Breast cancer (all types).
Shares Olaparib, Breast cancer (all types).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/